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Bilirubin is a heme metabolite generated by the concerted action of the enzymes heme
oxygenase and biliverdin reductase. Although long considered a toxic byproduct of heme
catabolism, recent preclinical, and clinical studies indicate the bilirubin exerts beneﬁcial
effects in the circulation. In the present study, we determined whether local administra-
tion of bilirubin attenuates neointima formation following injury of rat carotid arteries. In
addition, the ability of bilirubin to regulate the proliferation and migration of human arterial
smoothmuscle cells (SMCs) was investigated. Local perivascular administration of bilirubin
immediately following balloon injury of rat carotid arteries signiﬁcantly attenuated neointima
formation. Bilirubin-mediated inhibition of neointimal thickening was associated with a sig-
niﬁcant decrease in ERK activity and cyclin D1 and A protein expression, and an increase in
p21 and p53 protein expression in injured blood vessels.Treatment of human aortic SMCs
with bilirubin inhibited proliferation and migration in a concentration-dependent manner
without affecting cell viability. In addition, bilirubin resulted in a concentration-dependent
increase in the percentage of cells in the G0/G1 phase of the cell cycle and this was par-
alleled by a decrease in the fraction of cells in the S and G2M phases of the cell cycle.
Finally, bilirubin had no effect on mitochondrial function and ATP content of vascular SMCs.
In conclusion, these studies demonstrate that bilirubin inhibits neointima formation after
arterial injury and this is associatedwith alterations in the expression of cell cycle regulatory
proteins. Furthermore, bilirubin blocks proliferation and migration of human arterial SMCs
and arrests SMCs in the G0/G1 phase of the cell cycle. Bilirubin represents an attractive
therapeutic agent in treating occlusive vascular disease.
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INTRODUCTION
Bilirubin is a heme metabolite that is formed by the sequential
action of heme oxygenase (HO) and biliverdin reductase. HO
oxidatively degrades heme into equimolar amounts of biliverdin,
iron, and carbon monoxide while biliverdin reductase rapidly
metabolizes biliverdin to bilirubin. Bilirubin circulates in blood
bound to albumin and eventually enters the liver where it is glu-
curonidated by UDP-glucuronyltransferase 1A1 (UGT1A1) and
excreted into the bile ducts for elimination. Although long con-
sidered a toxic waste product of heme catabolism, bilirubin has
emerged as an important protective molecule in the circulation.
Early in vitro studies demonstrated that bilirubin is an efﬁcient
antioxidant under physiological conditions (Stocker et al., 1987a).
Both free and albumin-bound bilirubin scavenges peroxyl rad-
icals and protects low-density lipoprotein against peroxidation
(Stocker et al., 1987b;Wu et al., 1996). These ﬁndings were subse-
quently extended to show that bilirubin reacts with other reactive
oxygen and nitrogen species including hypochlorous acid, sin-
glet oxygen, hydroxyl radical, nitric oxide, and peroxynitrite (see
Stocker, 2004). Indeed, numerous studies have demonstrated a
cytoprotective role for bilirubin in response to various oxidative
insults (Yamaguchi et al., 1996; Clark et al., 2000; Dore et al.,
2009; Wei et al., 2009; Jansen et al., 2010). In addition, biliru-
bin exerts critical anti-inﬂammatory actions in the vasculature. It
attenuates endothelial expression of leukocyte adhesionmolecules
and prevents the rolling, adhesion, and inﬁltration of leukocytes
into the vessel wall (Vachharajan et al., 2000; Soares et al., 2004).
Given the fundamental role of oxidative stress and inﬂammation
in the pathogenesis of vascular disease, the antioxidant, and anti-
inﬂammatory actions of bilirubin may serve to defend against
this disorder. Consistent with this notion, several observational
studies have demonstrated an inverse correlation between serum
bilirubin levels and coronary artery disease in humans (Schw-
ertner et al., 1994; Hopkins et al., 1996). Similarly, high serum
bilirubin is associated with a reduced incidence of atherosclero-
sis and hypertension (Papadakis et al., 1999; Novotny and Vitek,
2003). Remarkably, the FraminghamOffspring Study revealed that
men with greater serum bilirubin levels have a lower risk of car-
diovascularmortality (Djousse et al., 2001). Furthermore, subjects
with mild life-long hyperbilirubinemia arising from Gilbert Syn-
drome, a genetic disorder where the conjugation and excretion
of bilirubin is impaired due to an inactivating polymorphism in
the promoter region of the gene coding for UGT1A, results in a
signiﬁcant reduction of risk for cardiovascular death compared
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to individuals without the syndrome (Hirschﬁeld and Alexander,
2006; Lin et al., 2006).
Preclinical studies also support a beneﬁcial role for bilirubin
in vascular disease. Elevations in endogenous circulating lev-
els of bilirubin attenuate hypertension in mice and rats while
the exogenous administration of bilirubin ameliorates ischemia–
reperfusion injury in various animal models (Pﬂueger et al., 2005;
Ollinger et al., 2007b; Vera et al., 2009). Parenteral treatment
with bilirubin improves endothelial function in atherogenic mice
(Kawamura et al., 2005). Interestingly, neointimal lesions that
develop following carotid artery balloon injury are dramatically
reduced in Gunn rats, a congenital model of hyperbilirubinemia
arising from defective UGT1A1 activity (Ollinger et al., 2005).
Furthermore, local or systemic administration of the bilirubin
precursor, biliverdin, suppresses neointima formation following
injury of rat carotid arteries (Nakao et al., 2005; Ollinger et al.,
2005) while ex vivo application of biliverdin to veins prior to graft-
ing abolishes intimal hyperplasia in a rat arterialized vein-graft
model (Nakao et al., 2005). However, it remains to be established
whether the exogenous delivery of bilirubin is also able to block
intimal thickening following vascular damage. Accordingly, the
present study determined whether local administration of biliru-
bin attenuates neointima formation and the expression of cell cycle
regulatory proteins in rat injured carotid arteries. In addition, this
study investigated the effect of bilirubin on the proliferation and
migration of human arterial smooth muscle cells (SMCs).
MATERIALS AND METHODS
MATERIALS
Sodium dodecyl sulfate (SDS), Tris, dimethyl sulfoxide (DMSO),
penicillin, Tes, streptomycin, neomycin, trypan blue, propidium
iodide, l-glutamine, trypsin, RNase, ethylenediaminetetraacetic
acid (EDTA), bromophenol blue, and glycerol were from Sigma-
Aldrich (St. Louis, MO, USA). M199 media, bovine calf serum,
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT)were fromInvitrogen (Carlsbad,CA,USA).Ketamine
and xylazine were purchased from Butler Schein Animal Health
Corporation (Dublin, OH, USA). Unconjugated bilirubin was
from Frontier Scientiﬁc (Logan, UT, USA). Antibodies against
cyclin D1, cyclin E, cyclin A, p21, p27, p53, and β-actin were
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). A
polyclonal antibody against HO-1 was from Assay Designs (Ann
Arbor, MI, USA) while antibodies against phospho-ERK1/2 and
ERK1/2 were from Cell Signaling (Beverly, MA, USA).
RAT CAROTID ARTERY BALLOON INJURY
Male SpragueDawley rats (400–500 g)were obtained fromCharles
River Laboratories, (Wilmington, MA, USA) and maintained on
standard rat chow and water ad libitum with 12 h light–dark
cycles. All experimental procedures conformed to the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources, 1996) and
were approved by the institutional animal use and care commit-
tee. Animals were anesthetized with an intravenous injection of
ketamine (100mg/kg) and xylazine (7.5mg/kg), and a Fogarty
2F embolectomy catheter (Baxter Healthcare Corporation, Deer-
ﬁeld, IL, USA) was introduced into the external carotid branch
through an arteriotomy site and advanced to the aortic arch. The
balloonwas then inﬂated andwithdrawn three times with rotation
along the length of the common carotid artery, as we previously
described (Tulis et al., 2001a; Granada et al., 2005; Peyton et al.,
2009, 2011). The catheter was then removed, the external carotid
artery ligated, overlying tissue sutured, and the skin closed with
rodent wound clips. In some cases, a local polymer-based delivery
system was used to administer bilirubin to the vessel wall immedi-
ately after injury and closure of the external carotid arteriotomy.
Bilirubin (1mg) was dissolved in 50μL DMSO and mixed into
200μL of a 25% solution of copolymer gel (Pluronic F-127; BASF
Corporation, Mount Olive, NJ, USA). The bilirubin-containing
gel was applied topically and circumferentially on the exposed
adventitia of the carotid artery. A separate control group of ani-
mals received a vehicle (DMSO)-containing gel. At various times
after arterial injury, animals were sacriﬁced by an anesthetic over-
dose followed by pneumothorax and exsanguination, and carotid
arteries collected for analysis.
HISTOLOGY
Following sacriﬁce, the thoracic aorta was clamped and normal
saline was perfused trans-cardially followed by 10% buffered for-
malin in phosphate-buffered saline. The carotid arteries were
then excised, parafﬁn-embedded, and sections (5μm) stained
with Verhoeff–Van Gieson for measurement of vessel dimen-
sions. Microscopic quantiﬁcation of vessel dimensions was per-
formed using Image-Pro Plus (Media Cybernetics Incorporated,
Bethesda, MD, USA) and Adobe Photoshop software (Adobe Sys-
tems, Mountain View, CA, USA) linked through a digital camera
(QICAM Fast 1394; Hitschfel Instruments Incorporated) to an
Olympus model BX41TF light microscope (Olympus America
Inc., Center Valley, PA, USA), as previously described (Tulis et al.,
2001a; Granada et al., 2005; Peyton et al., 2009, 2011).
WESTERN BLOTTING
Blood vessels were excised, pulverized in liquid nitrogen, and lysed
in electrophoresis buffer [125mM Tris (pH 6.8), 12.5% glycerol,
2% SDS, and trace bromophenol blue] and proteins separated by
SDS-PAGE. Following transfer to nitrocellulose membranes, blots
were blocked with PBS and non-fat milk (5%) and then incubated
with antibodies directed against cyclinD1 (1:500), cyclin E (1:500),
cyclin A (1:500), p27 (1:300), p21 (1:500), p53 (1:100), phospho-
ERK(1:250), ERK (1;1000), HO-1 (1:1000), or β-actin (1:200).
Blots were washed in PBS, incubated with horseradish peroxidase-
conjugated goat anti-rabbit or rabbit anti-goat antibodies and
developed with commercial chemiluminescence reagents. Pro-
tein expression was quantiﬁed by scanning densitometry and
normalized with respect to β-actin or ERK1/2.
CELL CULTURE
Human aortic SMCs were obtained commercially (Lonza Inc.,
Allendale, NJ, USA) and cultured serially in M199 media con-
taining 20% bovine calf serum, 2mM l-glutamine, 20mM TES,
and 20mM HEPES, as previously described (Liu et al., 2011b).
Culture media were supplemented with 100 units/ml penicillin
and streptomycin, and cells propagated in an atmosphere of 95%
air – 5% CO2.
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CELL PROLIFERATION
Vascular SMCs were seeded (2× 104 cells) onto six-well plates
and grown overnight. The next day cells were incubated with fresh
culture media in the absence or presence of bilirubin. Media with
appropriate additions were replenished every 2 days. Cell number
determinations were made after 4 days by dissociating cells with
trypsin (0.05%):EDTA(0.53mM)and counting cells in aBeckman
Z1 Coulter Counter (Beckman Coulter, Fullerton, CA, USA).
CELL CYCLE PROGRESSION
Cell cycle progression was monitored by ﬂow-activated cell sort-
ing (Peyton et al., 2009). Vascular SMCs were grown in culture
media in the absence or presence of bilirubin for 24 h. Cells were
then collected,washed in PBS,pelleted by centrifugation (1000× g
for 5min), suspended in 70% ethanol, and ﬁxed overnight at 4˚C.
Fixed cells were then incubated with propidium iodide (50μg/ml)
and RNAse A (100μg/ml) for 1 h at room temperature. DNA
ﬂuorescence was measured in a Becton Dickinson FACScan ﬂow
cytometer (Franklin Lakes,NJ,USA) and histograms of DNA con-
tent analyzed using Modﬁt (Verity Software) to determine the
fractions of the population in each phase of the cell cycle (Peyton
et al., 2009).
CELL MIGRATION
Vascular SMCmigration was assessed using a scratch wound assay
(Peyton et al., 2011). Conﬂuent cell monolayers were scratched
with a sterile 200μl pipette tip and treated with culture media in
the presence or absence of bilirubin. Cells were photographed
immediately after injury and 18 h later with a digital camera
(QImaging QICAM; Hitschfel Instruments, Inc., St. Louis, MO,
USA). The wound area was thenmeasured to determine the extent
of cell migration.
CELL VIABILITY
Vascular cell viability was assessed by measuring the uptake of the
membrane-impermeable dye trypan blue. Cells were incubated
with trypsin (0.25%), collected, diluted (1:4) with trypan blue,
and examined by microscopy. Viability was assessed by the frac-
tion of cells that excluded the dye, as previously reported (Wei
et al., 2009).
MITOCHONDRIAL ACTIVITY
Mitochondrial function was assessed using the tetrazolium salt
MTT, which is efﬁciently reduced by mitochondrial dehydroge-
nases to a purple formazan product (Liu et al., 2011a). Cells were
incubated with MTT (0.5mg/ml) at 37˚C for 4 h to allow the for-
mationof formazan crystals. ResidualMTTwas removed and crys-
tals dissolved by incubation with DMSO for 10min. Absorbance
was measured by spectrophotometry at 540 nm wavelength using
a plate reader (μQuant spectrophotometer, Bio-Tek Instruments,
Winooski, VT, USA). Mitochondrial activity was normalized for
cell number and expressed relative to control, untreated cells.
ATP MEASUREMENT
ATP levelsweredeterminedusing aCellTiter-Glo luciferase/luciferin
reaction assay (Promega,Madison,WI,USA).Cellswere incubated
with theATPAssayMixReagent containing luciferin and luciferase
for 10min at room temperature. Luminescence was measured
using a GloMax™Luminometer (Promega, Madison, WI, USA)
and ATP levels normalized for cell number and expressed relative
to control, untreated cells.
STATISTICS
Results are expressed as mean± SEM. Statistical analyses were
performed with the use of a Student’s two-tailed t -test and an
analysis of variance with the Bonferroni post hoc test when more
than two treatment regimenswere compared.P values< 0.05were
considered statistically signiﬁcant.
RESULTS
Balloon injury of rat carotid arteries resulted in signiﬁcant neoin-
tima formation. Figure 1A shows representative cross-sections
of perfusion-ﬁxed, Verhoeff–Van Gieson-stained tissues obtained
from animals 2 weeks after balloon injury. Animals treated with
an empty gel exhibited a substantial concentric neointima but a
markedly diminished neointima was observed in vessels exposed
to a gel containing bilirubin. Morphometric measurements indi-
cate that neointimal area, neointimal thickness, and neointi-
mal/medial wall area ratio were all signiﬁcantly reduced by biliru-
bin (Figure 1B). Despite a 65% reduction in neointima/medial
wall ratio in bilirubin-treated vessels, medial wall area was unaf-
fected by bilirubin. The decrease in neointima formation following
the administration of bilirubin was accompanied by pronounced
alterations in the expression of cell cycle regulatory proteins
(Figure 2A). Arterial injury resulted in a signiﬁcant increase in
the levels of cyclin D1, cyclin A, and p21 protein, and a decrease in
the expression of p27 protein in the vessel wall.However,bilirubin-
treated vessels exhibited diminished expression of cyclin D1 and
cyclin A protein following arterial injury whereas p27 protein
expression was unaffected. Interestingly, bilirubin exposed ves-
sels demonstrated a dramatic increase in the expression of the
transcription factor p53, a moderate yet signiﬁcant increase in p21
expression, and a signiﬁcant decrease in ERK activation after vessel
injury (Figures 2A,B). Arterial injury also caused a pronounced
increase in the expression of HO-1 that was unaffected by the
administration of bilirubin (Figure 2C).
In order to understand the underlying mechanism by which
bilirubin inhibits neointima formation, the effect of bilirubin on
the function of vascular SMCswas examined. Treatment of human
aortic SMCs with bilirubin resulted in a concentration-dependent
decrease in cell number beginning at 10μM (Figure 3A). In con-
trast, bilirubin hadno effect on the viability of SMCs, as assessed by
trypan blue exclusion (Figure 3B). The antiproliferative action of
bilirubinwas associatedwith the arrest of SMCs in theG0/G1 phase
of the cell cycle. Incubation of human aortic SMCs with bilirubin
resulted in a concentration-dependent increase in the percentage
of cells in the G0/G1 phase of the cell cycle and this was paralleled
by a decrease in the fraction of cells in the S and G2M phases of
the cell cycle (Figure 4). Finally, bilirubin also retarded the migra-
tion of SMCs after scratch wounding. Treatment of human aortic
SMCswith bilirubin caused a concentration-dependent inhibition
of cell migration starting at a concentration of 20μM (Figure 5).
In contrast, bilirubin had no effect on mitochondrial function or
cellular ATP levels (Figures 6A,B).
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FIGURE 1 | Bilirubin inhibits neointima formation in injured rat carotid
arteries. (A) Representative cross-sections of injured carotid arteries treated
with an empty gel (E) or a gel containing bilirubin (B) 2weeks after injury
(original magniﬁcation, 100×). (B) Morphometric analysis of neointima
formation 2weeks after arterial injury. Results are means±SEM (n=7).
*Statistically signiﬁcant effect of bilirubin.
DISCUSSION
The present study identiﬁes bilirubin as a critical regulator
of neointima formation following arterial injury. Topical, local
administration of bilirubin inhibits intimal thickening after vascu-
lar damage and this is associated with alterations in the expression
of several cell cycle regulatory proteins. In addition, bilirubin
blocks the proliferation andmigrationof humanarterial SMCs in a
concentration-dependentmanner that is associatedwith the arrest
of vascular SMCs in the G0/G1 phase of the cell cycle, independent
of any change in cell viability,mitochondrial function, or intracel-
lular ATP concentration. These ﬁndings underscore a potentially
important therapeutic role for bilirubin in ameliorating occlusive
vascular disease.
The current study is the ﬁrst to demonstrate that exogenous
application of bilirubin attenuates vascular remodeling following
arterial injury. Bilirubin was applied topically to the adventitia of
blood vessels using a speciﬁc local copolymer that has been suc-
cessfully employed by our laboratory and others (Hu et al., 1999;
Granada et al., 2005; Peyton et al., 2009, 2011). This drug delivery
approach allows for the sustained release of drugs while circum-
venting possible non-speciﬁc or toxic effects associated with the
systemic administration of drugs. This may be especially relevant
in the case of bilirubin where high circulating levels of the bile
pigment can lead to neurotoxicity (Ostrow et al., 2004).We found
that local administration of bilirubin markedly suppresses neoin-
tima formation following arterial injury, demonstrating that this
bile pigment is capable of blocking the vascular response to injury.
The attenuation of lesion formation by bilirubin is associated with
diminished expression of the G1 cyclins, cyclin D1 and A, which
are critical for entry and progression of cells through S-phase
of the cell cycle and DNA synthesis (Sherr, 1994). Interestingly,
bilirubin also reduces ERK activity in injured blood vessels. Since
the activation of ERK is linked with the induction of cyclin D1
expression following mitogenic stimulation (Weber et al., 1997;
Villanueva et al., 2007), the ability of bilirubin to inhibit ERK activ-
ity may contribute to the downregulation of cyclin D1 expression
observed with this bile pigment after arterial injury. In addition,
bilirubin induces the expression of the cyclin-dependent kinase
inhibitor p21 and the transcription factor p53, which are estab-
lished inhibitors of SMC replication and neointimal hyperplasia
(Yang et al., 1996; Sanz-Gonzalez et al., 2007). Since p53 has
recently been demonstrated to directly induce the expression of
HO-1 (Nam and Sabapathy, 2011), which is a key modulator
of vascular remodeling (Aizawa et al., 1999; Togane et al., 2000;
Duckers et al., 2001; Tulis et al., 2001a), we examined whether
bilirubin-mediated increases in p53 expression in damaged blood
vessels are associated with elevations in HO-1 expression. Con-
sistent with our previous work (Tulis et al., 2001b), we found
that arterial injury results in a marked elevation in HO-1 protein
expression. However, this arterial injury-induced rise in HO-1
protein is unaffected by the administration of bilirubin despite
a prominent increase in p53 expression, reinforcing the notion
that the ability of p53 to stimulate HO-1 gene expression is both
stimulus- and cell-speciﬁc (Yu et al., 1999; Nam and Sabapathy,
2011). Our in vivo ﬁndings showing the bilirubin disrupts ERK
activity and the expression of cell cycle regulatory proteins fol-
lowing vascular injury are in-line with earlier studies in cultured
vascular SMCs and suggest that bilirubin retards injury-induced
arterial lesion formation by repressing cell cycle progression and
SMC proliferation (Ollinger et al., 2005, 2007c; Stoeckius et al.,
2012).
The present study also found that bilirubin is a robust inhibitor
of human vascular SMC growth. Bilirubin blocks the proliferation
of human aortic SMCs in a concentration-dependentmanner. Sig-
niﬁcantly, bilirubin inhibits vascular SMC growth in the absence
of cell death indicating that bilirubin acts via a cytostatic rather
than cytotoxic mechanism. Furthermore, analysis of cell cycle dis-
tribution reveals that bilirubin inhibits cell cycle progression by
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FIGURE 2 | Effect of bilirubin on the expression or phosphorylation of
cell cycle regulatory proteins, ERK1/2, or HO-1 following rat carotid
artery balloon injury. (A) Expression of cyclin D1, cyclin E, cyclin A, p21, p27,
p53, and β-actin protein in control and injured arteries treated with an empty
(E) gel or a gel containing bilirubin (B) 2 days after injury. (B) Expression of
phospho-ERK1/2 and total ERK1/2 in control and injured arteries treated with
an empty (E) gel or a gel containing bilirubin (B) 2 days after injury. (C)
Expression of HO-1 in control and injured arteries treated with an empty (E)
gel or a gel containing bilirubin (B) 2 days after injury. Quantiﬁcation of relative
protein levels was achieved by scanning densitometry. Results are
means±SEM (n=3–5). *Statistically signiﬁcant effect of arterial injury.
+Statistically signiﬁcant effect of bilirubin.
speciﬁcally arresting human aortic SMCs in theG0/G1 phase of the
cell cycle. These ﬁndings complement previous reports showing
that physiologically relevant concentrations of bilirubin attenuates
cell cycle progression and DNA synthesis in arterial SMCs derived
fromdifferent animal species or blood vessels (Ollinger et al., 2005,
2007c; Stoeckius et al., 2012).Growth inhibitory effects of bilirubin
have also been reported in human airway smoothmuscle and vari-
ous tumor cell lines demonstrating that the antimitogenic effect of
this bile pigment is not unique to vascular SMCs (Taille et al., 2003;
Rao et al., 2006; Ollinger et al., 2007a). The antiproliferative action
of bilirubin likely involves multiple mechanisms. Consistent with
our in vivo ﬁndings, bilirubin inhibits the activity of ERK, a cru-
cial kinase involved in S-phase entry, in cultured vascular SMCs
(Stoeckius et al., 2012). Moreover, inhibition of ERK activation by
bilirubin has been implicated in its ability to block airway SMC
growth (Taille et al., 2003). However, the transcription factor p53
appears to play an essential role in mediating the antiproliferative
action of bilirubin in vascular SMCs. We found that bilirubin is a
potent inducer of p53 expression in injured blood vessels. In addi-
tion, bilirubin promotes the expression of p53 in numerous cell
types and deletion of p53 abrogates the antiproliferative action
of bilirubin in murine SMCs (Ollinger et al., 2007a,c). Interest-
ingly, p53 also stimulates apoptotic signaling pathways and may
contribute to the apoptotic actions of bilirubin in SMCs grown
in serum-free or serum-restricted conditions (Liu et al., 2002;
Ollinger et al., 2007c).
www.frontiersin.org March 2012 | Volume 3 | Article 48 | 5
Peyton et al. Bilirubin inhibits neointima formation
FIGURE 3 | Bilirubin inhibits the proliferation of human vascular SMCs
without affecting cell viability. (A) Effect of bilirubin on the proliferation of
SMCs. (B) Effect of bilirubin on SMC viability. Cells were treated with serum
(20%) in the absence or presence of bilirubin (0–50μM) for 4 days. Results
are means±SEM (n=4–5). *Statistically signiﬁcant effect of bilirubin.
FIGURE 4 | Bilirubin inhibits cell cycle progression of human vascular
SMCs. Cells were treated with serum (20%) in the absence or presence of
bilirubin (0–50μM) for 24 h. Results are means±SEM (n=4). *Statistically
signiﬁcant effect of bilirubin.
Since vascular SMC proliferation and migration are tightly
coupled processes (Fukui et al., 2000), we also investigated
whether bilirubin inﬂuences vascular SMC migration. Indeed,
we found that bilirubin inhibits human aortic SMC migration
in a concentration-dependent manner. However, the blockade of
SMC migration is not as pronounced as the inhibition of SMC
FIGURE 5 | Bilirubin inhibits the migration of human vascular SMCs.
Freshly scraped cell monolayers were treated with serum (20%) in the
absence or presence of bilirubin (0–50μM) and cell migration was
determined 18 h later. Results are means±SEM (n=3). *Statistically
signiﬁcant effect of bilirubin.
FIGURE 6 | Bilirubin has no effect on mitochondrial function or ATP
content in human vascular SMCs. (A) Effect of bilirubin on mitochondrial
function. (B) Effect of bilirubin on ATP content. Cells were treated with
serum (20%) in the absence or presence of bilirubin (0–50μM) for 24 h.
Results are means±SEM (n=3).
proliferation and is only observed at high bilirubin concentrations.
Failure of low concentrations of bilirubin to repress SMC migra-
tion is consistentwith a recently published study in rat aortic SMCs
(Rodriguez et al., 2010). Although themechanism bywhich biliru-
bin attenuates SMCmigration is not known itmay also involve the
induction of p53 since this transcription factor has been demon-
strated to block SMCmigration (Rodriguez-Compos et al., 2001).
Frontiers in Pharmacology | Drug Metabolism andTransport March 2012 | Volume 3 | Article 48 | 6
Peyton et al. Bilirubin inhibits neointima formation
In addition, p21 may also contribute to the antimigratory action
of bilirubin since overexpression of p21 in vascular SMCs has been
shown to inhibit their migration (Fukui et al., 1997). However, it
does not appear that alterations in mitochondrial function or ATP
production contribute to the antiproliferative or antimigratory
effect of bilirubin.
The ability of bilirubin to inhibit neointima formation by
blocking vascular SMC proliferation and migration identiﬁes this
bile pigment as an attractive agent in preventing stenosis of blood
vessels following surgical interventions to treat atherosclerosis. In
particular, perivascular application of bilirubin to veins or arteries
prior to or immediately after grafting may promote graft survival
following coronary artery bypass surgery. Alternatively, the use of
bilirubin-eluting stents may reduce the incidence of restenosis fol-
lowing percutaneous coronary balloon angioplasty. Interestingly,
a recent clinical study found that serum bilirubin is an indepen-
dent predictor of coronary in-stent stenosis (Kuwano et al., 2011).
Patients exhibiting elevated levels of bilirubin have a lower rate
of stenosis compared to patients with low serum bilirubin, pro-
viding additional support for the use of bilirubin-coated stents
in patients undergoing coronary stenting. Finally, since clinical
studies show that elevations in serum bilirubin protect against
coronary and peripheral artery disease and improve clinical out-
comes following surgical interventions to treat vascular disease,
the development of pharmacological inhibitors that raise circulat-
ing levels of bilirubin may provide a useful strategy in preventing
occlusive vascular disorders (Schwertner et al., 1994;Hopkins et al.,
1996; Perlstein et al., 2008; Kuwano et al., 2011). In this regard, the
design of speciﬁc pharmacological inhibitors that target the con-
jugating enzyme UGTTA1 offers a promising approach in raising
endogenous bilirubin levels (Vera et al., 2009; Durante, 2010).
In summary,we demonstrated that bilirubin inhibits neointima
formation after arterial injury in the rat and the proliferation and
migration of human SMCs. The antiproliferative and antimigra-
tory actions of bilirubin are concentration-dependent and associ-
ated with the arrest of SMCs in the G0/G1 phase of the cell cycle.
Thus, local delivery of bilirubin to blood vessels or augmentation
of endogenous circulating levels of bilirubin represent promising
therapeutic approaches in treating arterial disease.
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